Ipsen takes €669M hit as palovarotene's prospects wither

Profits and loss document with calculator and pen
Analysts see little scope for near-term news to lift the gloom that has settled over Ipsen. (a-wrangler/iStock/Getty Images Plus)

Ipsen has recorded a €669 million ($728 million) partial impairment on a rare disease drug it bought last year. The prospects of the drug, palovarotene, took back-to-back hits around the end of 2019, leading Ipsen to dramatically dial down its expectations.

France’s Ipsen acquired retinoic acid receptor gamma agonist palovarotene in its $1.3 billion takeover of Clementia Pharmaceuticals. At the time, David Meek, then the CEO of Ipsen, said the candidate was “largely derisked.” Subsequent events have shown that statement to be overly optimistic and put the prospect of Ipsen generating a return on the acquisition in jeopardy.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Ipsen set out its current thinking in its 2019 results on Thursday. Responding to a partial clinical hold and failed futility analysis, Ipsen recorded a €669 million partial impairment in the results. Ipsen paid $1 billion upfront to buy Clementia and gain control of palovarotene last year.

Management disclosed the partial impairment alongside a downgrading of their expectations for the midterm prospects of palovarotene. Ipsen now expects its sales in 2022 to exceed €2.8 billion, down from a forecast floor of €3.2 billion under its old guidance. The change reflects the assumption that palovarotene won’t generate any revenues in 2022.

While the chances of palovarotene living up to the expectations that fueled Ipsen’s $1.3 billion deal are shrinking, the French drug developer is yet to give up on the asset. Instead, Ipsen is continuing to assess data from the phase 3 that failed the futility analysis and working to respond to the FDA questions that triggered the partial clinical hold.

Ipsen hopes these activities will enable it to define the next steps for palovarotene “as quickly as possible.” However, analysts see little scope for near-term news to lift the gloom that has settled over Ipsen. 

“We see few opportunities to mitigate pessimistic sentiment and relieve pressure on the shares, exacerbated by the recent regulatory and clinical setbacks for palovarotene and the departure of CEO David Meek,” analysts at Jefferies wrote in a note to investors. 

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.